SG/PUT/VERTEX PHARMACEUTICALS/500/0.1/20.06.25 | Real-time Bid/Ask 10:51:51 03/07/2024 pm IST | ||
| 5.65 EUR / 5.85 EUR | +0.88% |
|
| Current month | +1.42% | ||
| 1 month | -19.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 5.52 | -3.16% |
| 02/24/02 | 5.7 | -0.70% |
| 01/24/01 | 5.74 | +2.14% |
| 28/24/28 | 5.62 | +0.72% |
| 27/24/27 | 5.58 | -1.93% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 12:09 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SY03XL |
| ISIN | DE000SY03XL0 |
| Date issued | 30/05/2024 |
| Strike | 500 $ |
| Maturity | 20/06/2025 (352 Days) |
| Parity | 10 : 1 |
| Emission price | 7.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.59 € |
|---|---|
| Lowest since issue | 5.15 € |
| Spread | 0.2 € |
| Spread % | 3.42% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
468.3
USD
Spread / Average Target
-1.16%
- Stock Market
- Warrants
- Warrant
